Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ATHA

Avoid These 2 Recently Downgraded Stocks

With the increasing odds of a recession and the expected continuation of the bear market, it could be difficult for fundamentally weak stocks to find support anytime soon. Our proprietary rating system has recently downgraded Athira Pharma (ATHA) and Futu Holdings (FUTU) to Sell because of their weak financials and…

4 Analysts Have This to Say About Athira Pharma

4 Analysts Have This to Say About Athira Pharma

Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Athira Pharma Stock Is Plunging

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease.

Athira Pharma Shares Fall To 52-Week Low - Read Why

Athira Pharma Inc (NASDAQ:ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (AD). The study did not meet the primary endpoint of a statistically significant change in ERP P300 Latency for the modified intent to treat…

Earnings Preview: Athira Pharma

Athira Pharma (NASDAQ:ATHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Athira Pharma will report an earnings per share (EPS) of $-0.54.

1

Organisations

Southwest Airlines

B of A Securities

Coinbase Global

Evercore ISI Group

Marathon Digital Holdings

Crispr rapeutics

Robert Half International

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play